Adverum to Host Conference Call and Webcast to Highlight Updated ADVM-022 Development Plans in Wet AMD, Recent Business Progress, and Fourth Quarter 2020 Financial Results

Rhea-AI Summary

Adverum Biotechnologies (Nasdaq: ADVM) will host a conference call on March 1, 2021, at 1:30 pm PT/4:30 pm ET to discuss the progress of its gene therapy candidate ADVM-022 for wet age-related macular degeneration (AMD) and to report Q4 2020 financial results. Key Opinion Leader Dr. Arshad M. Khanani will participate in the call. Investors can access the live webcast on the company’s website. The archived audio will be available for 30 days post-call.

Key Opinion Leader Arshad M. Khanani, M.D., M.A., director of clinical research, Sierra Eye Associates, and OPTIC and INFINITY trial investigator will participate on this call

REDWOOD CITY, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it will host a conference call and webcast on Monday, March 1, 2021 at 1:30 pm PT/4:30 pm ET to highlight significant progress in the development plans for ADVM-022 in wet AMD, recent business progress, and report fourth quarter 2020 financial results.

Key Opinion Leader, Arshad M. Khanani, M.D., M.A., director of clinical research, Sierra Eye Associates, and OPTIC and INFINITY trial investigator will participate on this call.

The live webcast will be accessible under Events and Presentations in the Investors section of the company's website. To participate in the conference call, dial 1-855-327-6837 (domestic) or 1-631-891-4304 (international) and refer to the “Adverum Biotechnologies’ Conference Call.” It is recommended call participants dial in 15 minutes in advance. The archived audio webcast will be available on the Adverum website following the call and will be available for 30 days.

About Adverum Biotechnologies
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. For more information, please visit www.adverum.com.

FAQ

When is Adverum Biotechnologies' conference call to discuss ADVM-022?

The conference call is scheduled for March 1, 2021, at 1:30 pm PT/4:30 pm ET.

What will be discussed during the conference call by Adverum Biotechnologies?

The call will highlight significant progress in ADVM-022's development for wet AMD and Q4 2020 financial results.

Who is participating in the Adverum Biotechnologies conference call?

Dr. Arshad M. Khanani, a key opinion leader and investigator for the OPTIC and INFINITY trials, will participate.

How can investors access the conference call by Adverum Biotechnologies?

Investors can access the live webcast through the Investors section of Adverum's website.